A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy - Sandler,A.; Gordon,M.; De Alwis,D.P.; Pouliquen,I.; Green,L.; Marder,P. (Clin Cancer Res, 2004)